Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21193681 | 0.83 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2AMAPTHPGD | |
| SCHEMBL16416951 | 0.83 | BRD4 (0.51) | ALDH1A1KMT2ASMN1; SMN2POLBNPC1 | |
| SCHEMBL20722097 | 0.80 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2AHTTMAPT | |
| SCHEMBL14636619 | 0.80 | HPGD (0.52) | ALDH1A1MEN1KMT2AHTTMAPT | |
| SCHEMBL4097862 | 0.78 | HPGD (0.50) | ALDH1A1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL28087185 | 0.77 | POLB (0.43) | KMT2AHTTMAPTSMN1; SMN2POLB | |
| SCHEMBL871448 | 0.76 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL21358281 | 0.75 | MAPT (0.47) | ALDH1A1MEN1KMT2AHTTMAPT | |
| SCHEMBL21411461 | 0.74 | ALDH1A1 (0.62) | ALDH1A1HTTMAPT | |
| SCHEMBL6903800 | 0.73 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2734529-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9718828-B2 | BTK Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170008899-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20140221333-A1 | BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-08-07 | — | — | US | disclosed |
| EP-2734529-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013010380-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008899-A1 | BTK INHIBITORS | BTK, SYK, ABL1 | ALDH1A1 4429/4885MEN1 3179/4885KMT2A 1571/4885 |
| US-20140221333-A1 | BTK INHIBITORS | BTK, SYK, ABL1 | ALDH1A1 4482/4885MEN1 2995/4885KMT2A 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.